Pfizer Inc. announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from pharmaceutical companies to biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis. Researchers and scientists have been relentlessly working to develop an investigational antiviral compound to prevent coronavirus infection (COVID-19), as well as evaluating other therapies that have scientific potential to help infected patients.
- Anti-Viral Compound Screening
Pfizer confirmed a lead compound and analogues are potent inhibitors of the SARS-CoV-2 3C-like (3CL) protease, based on the results of initial screening assays. Preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2. The company is also investing in materials that will accelerate a potential clinical study in the third quarter 2020, subject to positive completion of the pre-clinical confirmatory studies.
- Applying Pfizer’s Long History in Vaccine Research Development Expertise to Finalize Our Agreement with BioNTech
Pfizer Inc. and BioNTech SE have entered into a global collaboration agreement to co-develop BioNTech’s potential first-in-class, mRNA-based coronavirus vaccine for preventing COVID-19 infection. In March 2020, the companies began working together after releasing a letter of intent to collaborate. They will conduct clinical trials in the United States and Europe as early as April 2020, assuming regulatory clearance. The companies estimate that there is potential to supply vaccine doses by the end of 2020 subject to technical success and approval of regulatory authorities and then rapidly scale up to capacity to produce million doses in 2021. For the terms of the agreement, please see the press release page of Pfizer’s website.
- Analysis of Azithromycin as an Agent with Antiviral Activity
In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers will publish a review in Clinical Pharmacology and Therapeutics. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.
- Studying Pfizer’s Existing Medicines for Critical Patient Populations in Need
Pfizer is also in discussions with other institutions about additional studies including the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group. Two new studies: SAFER study (SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response) and the FASTER study (Facilitating A SARS CoV-2 Test for Rapid triage) will help demonstrate whether patients infected with COVID-19 have a higher risk of also developing pneumococcal pneumonia. The SAFER study will enroll 100 healthcare workers at the Royal Liverpool Hospital while the FASTER study will recruit 400 patients from the infectious disease ward at the Royal Liverpool Hospital suspected of having coronavirus. Enrollment has already begun, and data are expected over the next few months. For more details about the study, please see clinicaltrials.gov.
The company will continue to share information from its portfolio and emerging candidates that could benefit the many companies and organizations who are working quickly to provide solutions to combat this unprecedented healthcare crisis.
- Pfizer, Inc.: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
1,398 total views, 2 views today